<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073303</url>
  </required_header>
  <id_info>
    <org_study_id>1789-301-008</org_study_id>
    <nct_id>NCT04073303</nct_id>
  </id_info>
  <brief_title>BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence</brief_title>
  <official_title>BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and effectiveness of administering BOTOX for
      the treatment of Masseter Muscle Prominence (MMP) in adults.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">January 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of responders that show change in masseter muscle prominence (MMP)</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Investigator assessment of severity of MMP using the Masseter Muscle Prominence Scale (MMPS). Score ranges from 1 = minimal to 5 = very marked</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 18 Months</time_frame>
    <description>The number of patients who experienced one or more AEs during the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital sign values (blood pressure, respiratory rate, and pulse rate)</measure>
    <time_frame>Up to 18 Months</time_frame>
    <description>Summary statistics of change from baseline vital sign values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders who achieve a clinical target on a MMP scale</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Investigator assessment of MMP using a scale ranging from minimal to very marked</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders who achieve improvement using a self-assessment scale</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Improvement of MMP is self-assessed by the participant using a scale ranging from not at all pronounced to very pronounced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders that show improvement in MMP</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Improvement of MMP is self-assessed by the participant using a scale for change in MMP ranging from much improved to much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lower facial width</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Calculated from standardized images, measured in millimeters (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment effect</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Improvement from baseline of MMP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Masseter Muscle Prominence</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A (BOTOX®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Day 1 Administration of bilateral intramuscular injections into the masseter</description>
    <arm_group_label>Botulinum Toxin Type A (BOTOX®)</arm_group_label>
    <other_name>OnabotulinumtoxinA</other_name>
    <other_name>BOTOX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Masseter prominence at the Day 1 visit

          -  BMI ≤ 30 kg/m2 using the calculation: BMI = weight (kg)/[height (m)]2

          -  A female participant must be willing to minimize the risk of inducing pregnancy for
             the duration of the clinical study and follow-up periods

        Exclusion Criteria:

          -  Any medical condition that may put the participant at increased medical risk with
             exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome,
             amyotrophic lateral sclerosis, or any other condition that might interfere with
             neuromuscular function

          -  An anticipated need for surgery or overnight hospitalization during the study

          -  An anticipated need for treatment with botulinum toxin of any serotype for any
             indication during the study (other than study intervention)

          -  History of dental or surgical procedure for lower facial shaping or masseter muscle
             reduction

          -  Prior mid-facial and/or lower facial treatment with nonpermanent soft tissue fillers,
             synthetic implantations, autologous fat transplantation, fat-reducing injectables,
             and/or skin-tightening laser treatments within 6 months prior to Day 1

          -  Prior exposure to botulinum toxin of any serotype to the masseter muscle or lower face
             at any time, or to any other part of the body within the 6 months prior to Day 1

          -  History of temporomandibular joint disorder (TMJD)

          -  Masseter prominence due to other etiologies (eg, parotid gland infection, parotiditis,
             malignancy)

          -  Known allergy or sensitivity to any of the components of the study treatments or any
             materials used in the study procedures

          -  History of alcohol or drug abuse within 12 months of Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beta Bowen</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>1-877-277-8566</phone>
    <email>IR-CTRegistration@Allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Skin Advancement</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinaator</last_name>
      <phone>403-271-3627</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carruthers &amp; Humphrey Clinical Research</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Dermaesthetics</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>604-682-7577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Project Skin MD, LTD</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H1K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>604-732-0800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology &amp; Cosmetic Surgery</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>905-889-7497</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>010-82265571</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>86-027-83691785</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>025-83272015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Fourth Military Medical University Tangdu hospital</name>
      <address>
        <city>Xi'An</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of XI'AN Jiaotong University</name>
      <address>
        <city>Xi'An</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>022 - 60361044</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com.</description>
  </link>
  <link>
    <url>http://www.investigatordatabank.org/</url>
    <description>To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

